Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BBIO - BridgeBio Pharma, Inc.
Market Cap 5.14B P/E - EPS this Y 26.80% Ern Qtrly Grth -
Income -538.26M Forward P/E -11.81 EPS next Y -8.00% 50D Avg Chg 56.00%
Sales 218.6M PEG -0.14 EPS past 5Y - 200D Avg Chg 133.00%
Dividend N/A Price/Book N/A EPS next 5Y 67.30% 52W High Chg -12.00%
Recommedations 1.90 Quick Ratio 6.14 Shares Outstanding 187.13M 52W Low Chg 382.00%
Insider Own 5.27% ROA -40.08% Shares Float 115.78M Beta -
Inst Own 90.55% ROE - Shares Shorted/Prior 15.07M/13.41M Price 32.00
Gross Margin 98.88% Profit Margin -246.24% Avg. Volume 3,084,340 Target Price 49.83
Oper. Margin 1.77% Earnings Date Aug 1 Volume 2,656,761 Change -6.62%
Healthcare | Biotechnology | United States
About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc. News
08:26 AM What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
05/03/24 BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
05/03/24 BridgeBio Oncology Therapeutics launches with $200m funding
05/02/24 BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
05/02/24 BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
05/02/24 BridgeBio spinout launches with $200M for KRAS cancer drugs
05/01/24 Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
04/25/24 Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
04/10/24 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04/07/24 BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
03/27/24 TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
03/05/24 BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
03/05/24 Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
04:17 PM BridgeBio Pharma Announces Proposed Public Offering of Common Stock
04:05 PM BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug
03:00 AM Bayer pays $310M to buy into BridgeBio heart drug
02:30 AM BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe
02:30 AM BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
02/24/24 BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations
02/22/24 BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates
BBIO Chatroom

User Image JoeTheCheap Posted - 1 day ago

$BBIO Looked great out of the gate! Retest $30!!!

User Image jesse77727 Posted - 2 days ago

$BBIO solid report and great company development. So under the radar.

User Image jesse77727 Posted - 2 days ago

$BBIO buy set to add at 26.27

User Image OpenOutcrier Posted - 2 days ago

$BBIO (+2.1% pre) BridgeBio spins out oncology company as it focuses on heart drug - STAT https://ooc.bz/l/31965

User Image epsguid Posted - 2 days ago

$BBIO reported a loss of $0.05, consensus was ($0.40) via @eWhispers #epsbeat http://eps.sh/d/bbio

User Image DonCorleone77 Posted - 2 days ago

$BBIO BridgeBio reports Q1 EPS (20c), consensus (89c) Reports Q1 revenue $211.1M, consensus $14.03M. "In addition to the important scientific work we have done to advance our patient mission this quarter, we have also taken a first step towards streamlining our firm and thereby unlocking value for patients and investors alike," said Neil Kumar, Ph.D., founder and CEO of BridgeBio. "We believe the launch of BBOT better aligns investors with an opportunity that was being hidden in our pipeline, and our partnership with these new investors enables us to prosecute these oncology programs more quickly and with higher fidelity. In tandem with our progress in corporate simplification and balance sheet strengthening, we continue to prepare for what we believe will be a world class launch this year in ATTR-CM and we continue to enroll our achondroplasia, ADH1 and LGMD2I/R9 clinical trials, all of which are expected to complete enrollment this year."

User Image DonCorleone77 Posted - 2 days ago

$BBIO BridgeBio launches BBOT with $200M of private external capital BridgeBio Pharma has announced the completion of a $200M private financing of its former subsidiary, TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics, BBOT, to accelerate the development of its oncology portfolio. The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV, EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital, Aisling Capital, Casdin Capital, and Longwood Fund. BBOT will be advancing three initial programs: BBO-8520, a direct inhibitor of KRASG12C that binds to both the ON and OFF states of the protein; BBOT is currently enrolling patients in the ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer; BBO-10203, a PI3Kalpha:RAS breaker that blocks the specific interaction between RAS and PI3Ka to inhibit PI3Kalpha / AKT effector signaling in tumors while bypassing glucose metabolic signaling to avoid hyperglycemia; BBOT expects to file an Investigational New Drug application for BBO-10203 in Q2 2024 and, subject to clearance of the IND, will begin enrolling patients later this year; BBO-11818, a pan-KRAS inhibitor that targets both the ON and OFF states of KRASG12X for which BBOT expects to file an IND in early 2025.

User Image Stock_Titan Posted - 2 days ago

$BBIO BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update https://www.stocktitan.net/news/BBIO/bridge-bio-pharma-reports-first-quarter-2024-financial-results-and-9x6ycpgjcq73.html

User Image RonIsWrong Posted - 2 days ago

$BBIO

User Image RonIsWrong Posted - 2 days ago

$BBIO BBIO BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood Fund This capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies

User Image Stock_Titan Posted - 2 days ago

$BBIO BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline https://www.stocktitan.net/news/BBIO/bridge-bio-launches-bridge-bio-oncology-therapeutics-bbot-with-200m-n7wlbwnydx6c.html

User Image RonIsWrong Posted - 3 days ago

$BBIO grabbed back some shares yesterday and day before. @Irish_lass

User Image bubbybubster Posted - 3 days ago

$XBI rotated 20% of my portfolio out of energy to go heavy-weight on biotech last week. good move $FDMT $BBIO $SRRK

User Image Gravitationalsingularity Posted - 3 days ago

$BBIO Is the earnings report due out tomorrow? I cant find any official posting that says so.

User Image KWalzz Posted - 04/30/24

$BBIO now - after 4 addtl transactions - I'm avg 26 / 15k shares. is speculative, but imo on the brighter side of bio world.

User Image sampeper Posted - 04/29/24

$BBIO BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Allspring Global Investments Holdings LLC https://www.defenseworld.net/2024/04/29/bridgebio-pharma-inc-nasdaqbbio-shares-sold-by-allspring-global-investments-holdings-llc.html#google_vignette

User Image sampeper Posted - 04/29/24

$BBIO A Company Insider Recently Sold 2,500 Shares Of BridgeBio Pharma Inc [BBIO]. Should You Also Consider To Sale? https://knoxdaily.com/2024/04/29/a-company-insider-recently-sold-2500-shares-of-bridgebio-pharma-inc-bbio-should-you-also-consider-to-sale/

User Image WallStJesus Posted - 04/29/24

$BBIO BofA maintains BUY rating, $50 PT “Acoramidis outlook continues to look attractive ahead of competitor readout”

User Image sampeper Posted - 04/25/24

$BBIO shit is happened 🤪🤪🤪🤪🤪🤪🤪🤪

User Image DummiesNixGerafft Posted - 04/25/24

$CLRB $BBIO erste tranche drin. NGC 30% im minus. Jetzt up, wie $ASMB

User Image sampeper Posted - 04/23/24

$BBIO BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Federated Hermes Inc. https://www.defenseworld.net/2024/04/23/bridgebio-pharma-inc-nasdaqbbio-shares-sold-by-federated-hermes-inc.html#google_vignette

User Image bubbybubster Posted - 04/22/24

top biotechs with upcoming catalysts and promising pipelines $BBIO $FDMT $SRRK

User Image sampeper Posted - 04/22/24

$BBIO Vontobel Holding Ltd. Reduces Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) https://www.marketbeat.com/instant-alerts/nasdaq-bbio-sec-filing-2024-04-21/#google_vignette

User Image sampeper Posted - 04/19/24

$BBIO BridgeBio Pharma Inc [BBIO] Director Makes An Insider Sale Of 2,500 Shares Worth 85,000. https://knoxdaily.com/2024/04/18/bridgebio-pharma-inc-bbio-director-makes-an-insider-sale-of-2500-shares-worth-85000/#google_vignette

User Image ApexSeidon Posted - 04/19/24

$BBIO 22.5P 8/16exp $1.09M 2.6 Avg

User Image tompres1031 Posted - 04/15/24

$BBIO not looking good

User Image Capitulation_0 Posted - 04/15/24

$CYTK Blum you're better than that. Don't be like $BBIO...

User Image JoeTheCheap Posted - 04/15/24

$BBIO Where’s the love?

User Image OpenOutcrier Posted - 04/11/24

RECAP 4/11 +Pos Comments: $CROX + OTR $EGIO + Citron $BBIO + AF, STAT RECAP 4/11 -Neg Comments: $GL - Fuzzy Panda $JHX - Macquarie Live Breaking trading news www.openoutcrier.com

User Image AE4328 Posted - 04/11/24

$BBIO any news on this?

Analyst Ratings
JP Morgan Overweight Mar 20, 24
Cantor Fitzgerald Overweight Mar 19, 24
Cantor Fitzgerald Overweight Mar 11, 24
Mizuho Buy Mar 5, 24
HC Wainwright & Co. Buy Mar 4, 24
Citigroup Buy Feb 23, 24
BMO Capital Market Perform Jan 31, 24
HC Wainwright & Co. Buy Jan 29, 24
Cantor Fitzgerald Overweight Jan 22, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MCCORMICK FRANK Director Director Dec 26 Sell 42.06 100,000 4,206,000 627,689 12/28/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jul 18 Sell 35 1,500,000 52,500,000 25,120,991 07/19/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Apr 05 Sell 15.454 55,500 857,697 101,337 04/07/23
Kumar Neil CEO and President CEO and President Apr 05 Sell 15.4638 120,000 1,855,656 1,132,722 04/07/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Mar 03 Sell 10.9607 62,692 687,148 156,837 03/03/23
Kumar Neil CEO and President CEO and President Mar 03 Sell 10.9602 120,000 1,315,224 1,252,722 03/03/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Feb 16 Sell 12.86 17,717 227,841 219,529 02/21/23
Kumar Neil CEO and President CEO and President Feb 16 Sell 12.7 44,798 568,935 4,813,197 02/21/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Feb 03 Sell 11.0079 61,040 671,922 219,184 02/06/23
Kumar Neil CEO and President CEO and President Feb 03 Sell 11.0058 120,000 1,320,696 1,372,722 02/06/23
STEPHENSON BRIAN C Secretary, Treasurer.. Secretary, Treasurer & CFO Jan 05 Sell 7.6748 61,040 468,470 280,224 01/06/23
Kumar Neil CEO and President CEO and President Jan 05 Sell 7.6738 120,000 920,856 1,492,722 01/06/23
Ellis Andrea Director Director Mar 15 Buy 8.39 12,000 100,680 12,000 03/17/22
DANIELS RONALD J Director Director Dec 28 Buy 13.54 22,147 299,870 10,402 12/30/21
DANIELS RONALD J Director Director Dec 28 Sell 12.8 11,745 150,336 12/30/21
STEPHENSON BRIAN C See Remarks See Remarks Feb 18 Buy 62.5 8,000 500,000 300,043 02/18/21
Turtle Cameron See Remarks See Remarks Dec 29 Sell 69.64 19,500 1,357,980 12,568 12/29/20
Turtle Cameron See Remarks See Remarks Dec 29 Option 5.83 19,500 113,685 32,068 12/29/20
SCHELLER RICHARD H See Remarks See Remarks Dec 23 Sell 65.14 60,401 3,934,521 45,860 12/23/20
Turtle Cameron See Remarks See Remarks Nov 25 Option 17 5,000 85,000 13,310 11/25/20
Turtle Cameron See Remarks See Remarks Nov 25 Sell 47.12 5,000 235,600 12,568 11/25/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Nov 18 Option 1.05 10,000 10,500 277,751 11/18/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Nov 18 Sell 45 10,000 450,000 267,751 11/18/20
HOMCY CHARLES J Chairman of Pharmace.. Chairman of Pharmaceuticals Oct 19 Option 17 10,256 174,352 1,214,023 10/19/20
HOMCY CHARLES J Chairman of Pharmace.. Chairman of Pharmaceuticals Oct 19 Sell 41 10,256 420,496 1,203,767 10/19/20
Turtle Cameron See Remarks See Remarks Oct 02 Option 5.83 14,500 84,535 27,068 10/02/20
Turtle Cameron See Remarks See Remarks Oct 02 Sell 37.92 14,500 549,840 12,568 10/02/20
HOMCY CHARLES J Chairman of Pharmace.. Chairman of Pharmaceuticals Sep 29 Sell 37.22 99,257 3,694,346 1,203,767 09/29/20
Turtle Cameron See Remarks See Remarks Sep 22 Option 17 2,500 42,500 15,068 09/22/20
Turtle Cameron See Remarks See Remarks Sep 22 Sell 42.01 2,500 105,025 12,568 09/22/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Sep 22 Option 0.22 10,000 2,200 277,751 09/22/20
HENDERSON MICHAEL THOMAS Chief Business Offic.. Chief Business Officer Sep 22 Sell 40 10,000 400,000 267,751 09/22/20
Turtle Cameron See Remarks See Remarks Sep 16 Option 17 2,500 42,500 15,068 09/16/20
Turtle Cameron See Remarks See Remarks Sep 16 Sell 37.06 2,500 92,650 12,568 09/16/20